Based on these studies, Al-Mterin et al. [10] suggested that there is some evidence supporting the use of a panel of ICPMs as prognostic biomarkers (e.g., PD1, CTLA-4, TIM3, PD-L1, Gal-3, and Gal-9) for severe COVID-19 patients. The gene discussed is CTLA4; the disease is COVID-19.